Tissue factor pathway inhibitor: Then and now

Seminars in Thrombosis and Hemostasis

Volumn 123, Issue 19, 2015, Pages 881-886

  Ellery, Paul E R ^a   Adams, Murray J ^b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

factor V; hemophilia; protein S; thrombosis; tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; GLYCOSYLPHOSPHATIDYLINOSITOL; ISOPROTEIN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ALTERNATIVE RNA SPLICING; ANTICOAGULATION; ARTICLE; DISEASE ASSOCIATION; DRUG DISTRIBUTION; ENZYME INHIBITION; HEMOPHILIA; HUMAN; MOLECULAR WEIGHT; PHYSIOLOGY; THROMBOPHILIA; BLOOD CLOTTING; ENDOTHELIUM CELL; HEMOPHILIA A; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANIMAL; BLOOD; HISTORY; METABOLISM; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; HEMOPHILIA A; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIPOPROTEINS; PROTEIN S; THROMBOSIS;

EID: 84928553017     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1395153     Document Type: Article

References (91)

1. Wood J. P., Ellery P. E., Maroney S. A., Mast A. E. Biology of tissue factor pathway inhibitor. Blood: 2014; 123 19 2934 2943
2. Loeb L., Fleisher M. S., Tuttle L. The interaction between blood serum and tissue extract in the coagulation of blood: II. A comparison between the effects of the stroma of erythrocytes and of tissue extracts, unheated and heated, on the coagulation of the blood, and on the mechanism of the interaction of these substances with blood serum. J Biol Chem: 1922; 51 485 506
3. Loeb L., Fleisher M. S., Tuttle L. The interaction between blood serum and tissue extract in the coagulation of blood: I. The combined action of serum and tissue extract on fluoride, hirudin, and peptone plasma; the effect of heating on serum. J Biol Chem: 1922; 51 461 483
4. Schneider C. L. The active principle of placental toxin; thromboplastin; its inactivator in blood; antithromboplastin. Am J Physiol: 1947; 149 1 123 129
5. Thomas L. Studies on the intravascular thromboplastic effect of tissue suspensions in mice: a factor in normal rabbit serum which inhibits the thromboplastic effect of the sedimentable tissue component. Bull Johns Hopkins Hosp: 1947; 81 1 26 42
6. Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin; convertin, accelerin, prothrombinase. Scand J Clin Lab Invest: 1957; 9 27 1 183
7. Davie E. W., Ratnoff O. D. Waterfall sequence for intrinsic blood clotting. Science: 1964; 145 3638 1310 1312
8. MacFarlane R. G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature: 1964; 202 498 499
9. Biggs R., MacFarlane R. G. The reaction of haemophilic plasma to thromboplastin. J Clin Pathol: 1951; 4 4 445 459
10. Biggs R., Nossel H. L. Tissue extract and contact reaction in blood coagulation. Thromb Diath Haemorrh: 1961; 6 1 14
11. Marciniak E., Tsukamura S. Two progressive inhibitors of factor Xa in human blood. Br J Haematol: 1972; 22 3 341 351
12. Barrowcliffe T. W., Eggleton C. A., Stocks J. Studies of anti-Xa activity in human plasma. II: The role of lipoproteins. Thromb Res: 1982; 27 2 185 195
13. Carson S. D. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett: 1981; 132 1 37 40
14. Marlar R. A., Kleiss A. J., Griffin J. H. An alternative extrinsic pathway of human blood coagulation. Blood: 1982; 60 6 1353 1358
15. Morrison S. A., Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood: 1984; 63 6 1338 1347
16. Sanders N. L., Bajaj S. P., Zivelin A., Rapaport S. I. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood: 1985; 66 1 204 212
17. Hubbard A. R., Jennings C. A. Inhibition of tissue thromboplastin-mediated blood coagulation. Thromb Res: 1986; 42 4 489 498
18. Broze G. J. Jr, Miletich J. P. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci U S A: 1987; 84 7 1886 1890
19. Rao L. V., Rapaport S. I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood: 1987; 69 2 645 651
20. Broze G. J. Jr, Warren L. A., Girard J. J., Miletich J. P. Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatoma) cells using bovine factor Xa affinity chromatography. Thromb Res: 1987; 48 2 253 259
21. Broze G. J. Jr, Miletich J. P. Characterization of the inhibition of tissue factor in serum. Blood: 1987; 69 1 150 155
22. Girard T. Tissue factor pathway inhibitor. In: Sasahara A. A., Loscalzo J., eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY M. Dekker: 1997; 225 260
23. Wun T. C., Kretzmer K. K., Girard T. J., Miletich J. P., Broze G. J. Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem: 1988; 263 13 6001 6004
24. Wun T. C., Huang M. D., Kretzmer K. K., et al. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells. A comparative study. J Biol Chem: 1990; 265 27 16096 16101
25. Novotny W. F., Palmier M., Wun T. C., Broze G. J. Jr, Miletich J. P. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood: 1991; 78 2 394 400
26. Piro O., Broze G. J. Jr. Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost: 2005; 3 12 2677 2683
27. Chang J. Y., Monroe D. M., Oliver J. A., Roberts H. R. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost: 1999; 81 1 45 49
28. Zhang J., Piro O., Lu L., Broze G. J. Jr. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation: 2003; 108 5 623 627
29. Girard T. J., Warren L. A., Novotny W. F., Bejcek B. E., Miletich J. P., Broze G. J. Jr. Identification of the 1.4. kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein. Thromb Res: 1989; 55 1 37 50
30. Ellery P. E., Maroney S. A., Martinez N. D., Wickens M. P., Mast A. E. Translation of human tissue factor pathway inhibitor-β mRNA is controlled by alternative splicing within the 5′ untranslated region. Arterioscler Thromb Vasc Biol: 2014; 34 1 187 195
31. Bajaj M. S., Kuppuswamy M. N., Saito H., Spitzer S. G., Bajaj S. P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A: 1990; 87 22 8869 8873
32. Werling R. W., Zacharski L. R., Kisiel W., Bajaj S. P., Memoli V. A., Rousseau S. M. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost: 1993; 69 4 366 369
33. Maroney S. A., Cunningham A. C., Ferrel J., et al. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost: 2006; 4 5 1114 1124
34. Crawley J., Lupu F., Westmuckett A. D., Severs N. J., Kakkar V. V., Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol: 2000; 20 5 1362 1373
35. Lupu C., Hu X., Lupu F. Caveolin-1 enhances tissue factor pathway inhibitor exposure and function on the cell surface. J Biol Chem: 2005; 280 23 22308 22317
36. Lupu C., Goodwin C. A., Westmuckett A. D., et al. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol: 1997; 17 11 2964 2974
37. Mast A. E., Acharya N., Malecha M. J., Hall C. L., Dietzen D. J. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol: 2002; 22 12 2099 2104
38. Ellery P. E., Hardy K., Oostryck R., Adams M. J. Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid-anchored forms of tissue factor pathway inhibitor. Clin Appl Thromb Hemost: 2008; 14 3 267 278
39. Girard T. J., Tuley E., Broze G. J. Jr. TFPI β is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood: 2012; 119 5 1256 1262
40. Piro O., Broze G. J. Jr. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation: 2004; 110 23 3567 3572
41. Iversen N., Sandset P. M., Abildgaard U., Torjesen P. A. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Thromb Res: 1996; 84 4 267 278
42. Lupu C., Poulsen E., Roquefeuil S., Westmuckett A. D., Kakkar V. V., Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol: 1999; 19 9 2251 2262
43. Tiemann C., Brinkmann T., Kleesiek K. Detection of the three Kunitz-type single domains of membrane-bound tissue factor pathway inhibitor (TFPI) by flow cytometry. Eur J Clin Chem Clin Biochem: 1997; 35 11 855 860
44. Sandset P. M. Tissue factor pathway inhibitor (TFPI)-an update. Haemostasis: 1996; 26 04 154 165
45. Novotny W. F., Girard T. J., Miletich J. P., Broze G. J. Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem: 1989; 264 31 18832 18837
46. Broze G. J. Jr, Lange G. W., Duffin K. L., MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis: 1994; 5 4 551 559
47. Novotny W. F., Brown S. G., Miletich J. P., Rader D. J., Broze G. J. Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood: 1991; 78 2 387 393
48. Hansen J. B., Huseby K. R., Huseby N. E., Sandset P. M., Hanssen T. A., Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol: 1995; 15 7 879 885
49. Augustsson C., Hilden I., Petersen L. C. Inhibitory effects of LDL-associated tissue factor pathway inhibitor. Thromb Res: 2014; 134 1 132 137
50. Novotny W. F., Girard T. J., Miletich J. P., Broze G. J. Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood: 1988; 72 6 2020 2025
51. Maroney S. A., Haberichter S. L., Friese P., et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood: 2007; 109 5 1931 1937
52. Jayachandran M., Sanzo A., Owen W. G., Miller V. M. Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am J Physiol Heart Circ Physiol: 2005; 289 5 H1908 H1916
53. Novotny W., Day K., Wun T-C, Nieces G. Platelet LACI is present in novel granules. Blood: 1990; 76 01 469
54. Maroney S. A., Cooley B. C., Ferrel J. P., Bonesho C. E., Mast A. E. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol: 2011; 31 4 821 826
55. Winckers K., ten Cate H., Hackeng T. M. The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev: 2013; 27 3 119 132
56. Adams M. Tissue factor pathway inhibitor: new insights into an old inhibitor. Semin Thromb Hemost: 2012; 38 2 129 134
57. Adams M. J., Oostryck R. A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples. Blood Coagul Fibrinolysis: 2000; 11 4 327 333
58. Knappe S., Gorczyca M. E., Jilma B., et al. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood. Thromb Haemost: 2013; 109 3 450 457
59. Maroney S. A., Cooley B. C., Ferrel J. P., et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci U S A: 2012; 109 10 3927 3931
60. Tardy-Poncet B., Piot M., Chapelle C., Berger C., Tardy B. Difference in TFPI levels between haemophilia A and B patients. Haemophilia: 2011; 17 2 312 313
61. Erhardtsen E., Ezban M., Madsen M. T., et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis: 1995; 6 5 388 394
62. Hilden I., Lauritzen B., Sorensen B. B., et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood: 2012; 119 24 5871 5878
63. Prasad S., Lillicrap D., Labelle A., et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood: 2008; 111 2 672 679
64. Dockal M., Hartmann R., Fries M., et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem: 2014; 289 3 1732 1741
65. Waters E. K., Genga R. M., Schwartz M. C., et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood: 2011; 117 20 5514 5522
66. Dockal M., Hartmann R., Knappe S., et al. Effect of increased tissue factor pathway inhibitor (TFPI) levels on factor Xa inhibition and global hemostasis in the presence of TFPI-antagonistic aptamer BAX 499. Blood: 2012; 120; 2207
67. Dockal M., Pachlinger R., Hartmann R., et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499 [Abstract]. Blood: 2012; 120 1104
68. Hackeng T. M., Seré K. M., Tans G., Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A: 2006; 103 9 3106 3111
69. Peraramelli S., Suylen D. P., Rosing J., Hackeng T. M. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Thromb Haemost: 2012; 108 2 266 276
70. Peraramelli S., Thomassen S., Heinzmann A., et al. Direct inhibition of factor VIIa by TFPI and TFPI constructs. J Thromb Haemost: 2013; 11 4 704 714
71. Ndonwi M., Tuley E. A., Broze G. J. Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood: 2010; 116 8 1344 1351
72. Ahnström J., Andersson H. M., Hockey V., et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood: 2012; 120 25 5059 5062
73. Wood J. P., Ellery P. E., Maroney S. A., Mast A. E. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol: 2014; 34 1 169 176
74. Reglińska-Matveyev N., Andersson H. M., Rezende S. M., et al. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. Blood: 2014; 123 25 3979 3987
75. Castoldi E., Simioni P., Tormene D., Rosing J., Hackeng T. M. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost: 2010; 8 2 294 300
76. Dahm A. E., Sandset P. M., Rosendaal F. R. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost: 2008; 6 2 393 395
77. Bos M. H., Camire R. M. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem: 2012; 287 31 26342 26351
78. Kane W. H., Davie E. W. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Natl Acad Sci U S A: 1986; 83 18 6800 6804
79. Kane W. H., Ichinose A., Hagen F. S., Davie E. W. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry: 1987; 26 20 6508 6514
80. Jenny R. J., Pittman D. D., Toole J. J., et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A: 1987; 84 14 4846 4850
81. Smith C. M., Hanahan D. J. The activation of factor V by factor Xa or alpha-chymotrypsin and comparison with thrombin and RVV-V action. An improved factor V isolation procedure. Biochemistry: 1976; 15 9 1830 1838
82. Foster W. B., Nesheim M. E., Mann K. G. The factor Xa-catalyzed activation of factor V. J Biol Chem: 1983; 258 22 13970 13977
83. Odegaard B., Mann K. Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem: 1987; 262 23 11233 11238
84. Viskup R. W., Tracy P. B., Mann K. G. The isolation of human platelet factor V. Blood: 1987; 69 4 1188 1195
85. Monković D. D., Tracy P. B. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem: 1990; 265 28 17132 17140
86. Wood J. P., Bunce M. W., Maroney S. A., Tracy P. B., Camire R. M., Mast A. E. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A: 2013; 110 44 17838 17843
87. Ndonwi M., Girard T. J., Broze G. J. Jr. The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va. J Thromb Haemost: 2012; 10 9 1944 1946
88. Duckers C., Simioni P., Spiezia L., et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood: 2008; 112 9 3615 3623
89. Vincent L. M., Tran S., Livaja R., Bensend T. A., Milewicz D. M., Dahlbäck B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα J Clin Invest: 2013; 123 9 3777 3787
90. Mast A. E., Broze G. J. Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood: 1996; 87 5 1845 1850
91. Schuijt T. J., Bakhtiari K., Daffre S., et al. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation: 2013; 128 3 254 266